VILAFINIL 200

What is VILAFINIL 200?

VILAFINIL 200 is a modern pharmaceutical agent belonging to the pharmacological group of psychostimulants and nootropic drugs with a pronounced promoting effect on cognitive functions. The drug is manufactured in the form of hard gelatin capsules for oral use, each containing a precisely calibrated dose of the active substance — 200 mg. The product is manufactured by Fortune Healthcare, a company known on the international market for the quality of its generic developments in the ASSURANS, CENFORCE, and MALEGRA categories. This medication is positioned as a means for correcting conditions associated with pathological daytime sleepiness and reduced mental performance. The pharmacodynamics of the drug are based on the selective activation of certain brain areas responsible for maintaining a state of wakefulness, without a pronounced effect on the peripheral nervous system.

Unlike classic amphetamine stimulants, VILAFINIL 200 demonstrates a significantly milder action profile and a lower potential for dependence formation. The drug does not cause euphoria or a sharp rise in blood pressure, making it acceptable for long-term use under medical supervision. The main purpose of the product is to restore the natural sleep-wake cycle, as well as to improve concentration, reaction speed, and short-term memory. The therapeutic effect develops gradually, reaching its peak a few hours after administration, allowing for the planning of intellectual workloads. Thanks to modern manufacturing technology, the bioavailability of the active component is stable and predictable, ensuring a consistent clinical result.

VILAFINIL 200 is often considered by specialists as the drug of choice for patients requiring prolonged maintenance of cognitive tone without the risk of nervous system exhaustion. In clinical practice, it is used for the symptomatic treatment of narcolepsy, obstructive sleep apnea, and shift work sleep disorder. The drug is not intended for self-medication and is dispensed upon a doctor's recommendation, as it requires preliminary diagnosis and the exclusion of cardiovascular contraindications. It is important to understand that VILAFINIL 200 does not replace physiological sleep, but only helps the body maintain the necessary level of activity during designated periods. Fortune Healthcare guarantees the compliance of each batch of the drug with international GMP standards, as confirmed by quality certificates.

What is VILAFINIL 200 prescribed for?

The main indications for the use of VILAFINIL 200 are conditions accompanied by pathological daytime sleepiness, which significantly reduces the quality of life and professional productivity. Most often, the drug is prescribed to patients with a confirmed diagnosis of narcolepsy — a chronic neurological disorder in which a person experiences uncontrollable sleep attacks throughout the day. In such cases, VILAFINIL 200 helps to stabilize the wakefulness cycle, reducing the frequency and intensity of sudden falling asleep episodes. The agent is also effective for obstructive sleep apnea syndrome, when night-time breathing disruption leads to chronic sleep deprivation and severe morning fatigue. Therapy with the drug allows for compensation of daytime sleepiness even if the underlying disease requires separate treatment or the use of CPAP devices.

The second important category of indications includes sleep disorders related to shift work, when the body's natural circadian rhythm is disrupted due to night shifts or frequent flights across time zones. VILAFINIL 200 helps workers who are forced to perform job duties at night to maintain a high level of attention and reaction speed, which is critically important for drivers, dispatchers, doctors, and security personnel. The drug does not cause sharp agitation or tremors, thus allowing fine motor skills and precision of movement to be preserved. In addition, the product can be used in the complex therapy of asthenic conditions after infectious diseases or traumatic brain injuries when a pronounced decrease in mental capacity is observed. In such cases, the drug is prescribed in short courses to restore cognitive potential.

In some clinical situations, VILAFINIL 200 is used as an adjunctive agent for attention deficit hyperactivity disorder in adults, although this indication is not officially approved in all countries. The drug helps to improve focus on tasks, reduce impulsiveness, and increase the ability to perform prolonged monotonous work. It is important to note that VILAFINIL 200 is not intended for the treatment of depression or anxiety disorders; however, as part of complex therapy, it can positively affect the secondary asthenia that accompanies these conditions. Prescribing the drug should always be based on a thorough history taking and the exclusion of other causes of sleepiness, such as anemia, hypothyroidism, or B vitamin deficiency. Only a physician can determine the appropriateness of using the product in each specific case.

Composition and active components of VILAFINIL 200

The active pharmaceutical ingredient of VILAFINIL 200 is modafinil — a synthetic compound belonging to the class of benzhydrylsulfinylacetamides. This molecule was first synthesized in the late 20th century and has since been actively studied as an alternative to traditional psychostimulants with a lower side effect profile. Modafinil acts primarily on hypothalamic centers that regulate wakefulness, in particular on neurons that produce orexin and histamine. Unlike amphetamines, it does not cause a massive release of dopamine in the striatum, so the risk of developing euphoria and psychological dependence is significantly lower. The mechanism of action also includes inhibition of dopamine reuptake, which increases its concentration in the synaptic cleft, but this process occurs more slowly and in a more controlled manner.

The composition of the VILAFINIL 200 capsule includes excipients that ensure the stability of the active substance and its proper absorption in the gastrointestinal tract. Among them are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate, which act as filler, disintegrant, and lubricant, respectively. The capsule shell is made of hypromellose, making the product suitable for patients who avoid animal-derived gelatin. Thanks to the balanced composition of excipients, rapid release of modafinil is achieved after ingestion, and its peak concentration in blood plasma is observed after two to three hours. The elimination half-life is about 12–15 hours, allowing the drug to be taken once daily without the need to split the dose.

The pharmacokinetic properties of VILAFINIL 200 are characterized by high bioavailability, which is not significantly affected by food intake, although fatty food may slightly slow down the rate of absorption. Metabolism of the active substance occurs primarily in the liver with the participation of cytochrome P450 system enzymes, particularly the CYP3A4 isoenzyme, which should be taken into account when co-administering other medications. Excretion of metabolites is carried out by the kidneys, so patients with impaired renal function may require dose adjustment. The drug penetrates well through the blood-brain barrier, providing its pronounced central effect. It is worth emphasizing that VILAFINIL 200 is not a hormonal agent and does not affect endocrine regulation, so its use is not accompanied by changes in body weight or metabolic disorders.

Dosage of VILAFINIL 200

The standard recommended dose of VILAFINIL 200 for adult patients is 200 mg once daily, which corresponds to one capsule of the medication. Administration is usually carried out in the morning or one hour before the start of a work shift in the case of correcting sleepiness during a shift schedule. For patients with narcolepsy, this dose is optimal for maintaining a stable level of wakefulness throughout the day without the need for an additional evening dose. In some cases, a physician may recommend an initial dose of 100 mg per day to assess individual tolerability, especially if the patient has concomitant liver or kidney diseases. Increasing the dose to 200 mg is carried out gradually, after clinical evaluation of the effect and the absence of adverse reactions.

The maximum daily dose of VILAFINIL 200 should not exceed 400 mg; however, such an increase is allowable only in conditions of insufficient efficacy of the standard dose and under strict medical supervision. Exceeding recommended doses does not lead to a proportional increase in the therapeutic effect, but significantly increases the risk of side effects such as headache, anxiety, or sleep disturbances. The duration of the treatment course is determined individually depending on the underlying disease: for narcolepsy, therapy can be long-term, whereas for shift work sleep disorder, the drug is used episodically. Elderly patients over 65 years of age are recommended to start with the minimum effective dose, as drug elimination slows down and sensitivity to its action increases in this group.

Dose adjustment of VILAFINIL 200 may be required for patients with impaired hepatic function, as this organ is responsible for the metabolism of the active substance. In severe hepatic impairment, the daily dose is usually reduced by half, while in mild to moderate renal impairment, no adjustment is required. It is important not to discontinue the drug abruptly after a long course, as this may cause withdrawal syndrome in the form of severe fatigue and sleepiness. Dose reduction should occur gradually, in steps of 50–100 mg per week, depending on individual response. Patients should remember that self-adjusting the dose without consulting a physician is unacceptable and can lead to undesirable consequences.

How to take VILAFINIL 200 correctly?

VILAFINIL 200 should be taken orally with a sufficient amount of water, preferably at the same time every day to maintain a stable concentration of the drug in the blood. The capsule should not be chewed or opened, as this may disrupt the pharmacokinetics of the active component and lead to uneven absorption. Intake of the drug can be done independently of food; however, if the patient experiences stomach discomfort, it is advisable to take the capsule after a light breakfast. Fatty and high-calorie food can delay the onset of action by one to two hours, so on days when rapid activation is required, it is better to avoid a heavy meal before taking the drug. For patients with a shift work schedule, optimal intake is one hour before the start of the night shift, allowing peak concentration to be reached precisely during the period of maximum load.

In case of a missed dose of VILAFINIL 200, the patient should take it as soon as possible if at least eight hours remain before the next scheduled dose. If the miss is noticed late, it is better to skip the missed capsule and return to the usual schedule the next day to avoid disrupting night sleep. Doubling the dose to compensate for a missed one is strictly prohibited, as this can cause excessive stimulation of the nervous system and the development of side effects. The drug should not be taken later than six to eight hours before planned sleep, as its long elimination half-life can make falling asleep difficult. Patients sensitive to stimulants are recommended to start taking the drug on a day off to evaluate their individual reaction in safe conditions.

During VILAFINIL 200 therapy, it is important to maintain adequate fluid intake, as the drug can reduce the sensation of thirst, increasing the risk of dehydration. It is also recommended to limit the consumption of caffeinated beverages, as combining them with modafinil can increase anxiety, tremor, and tachycardia. Women of reproductive age using hormonal contraceptives must take into account that VILAFINIL 200 can reduce their effectiveness, so it is recommended to use additional barrier methods of protection. The drug is not intended for use in children and adolescents under 18 years of age, as safety and efficacy in this age group have not been established. Before starting administration, it is mandatory to consult a doctor and undergo a basic examination of the cardiovascular system.

Side effects of VILAFINIL 200

The most common side effects of VILAFINIL 200 occurring in more than 5% of patients are headache, nausea, dry mouth, and decreased appetite. These symptoms are usually mild or moderate, occur at the beginning of therapy, and gradually disappear as the body adapts to the drug. Headache is most often localized in the frontal region and responds well to correction with conventional analgesics; however, if it intensifies, a doctor should be consulted. Nausea can be minimized by taking the capsule after meals, and dry mouth by frequent small sips of water or using moisturizing oral sprays. Decreased appetite may lead to minor weight loss, so patients with low body weight are recommended to monitor their caloric intake.

Uncommon adverse reactions of VILAFINIL 200 include anxiety, nervousness, insomnia, and palpitations, which occur mainly when exceeding the recommended dose or taking the drug late in the day. Some patients experience an increase in blood pressure, requiring regular monitoring, especially in individuals with a history of hypertension. Gastrointestinal disorders such as diarrhea or constipation are also possible, which usually resolve spontaneously without additional therapy. Rare but serious side effects are allergic reactions, including skin rash, urticaria, angioedema, and in isolated cases — Stevens-Johnson syndrome. The appearance of any skin rashes or facial swelling is grounds for immediate discontinuation of the drug and seeking medical care.

Patients should be aware that VILAFINIL 200 can cause psychiatric reactions, such as agitation, irritability, hallucinations, or manic episodes, especially in individuals with a history of psychiatric illness. If unusual mood changes, aggressiveness, or suicidal thoughts appear, it is necessary to urgently inform a doctor. The individual reaction of the body to the drug can vary significantly depending on age, sex, genetic metabolic characteristics, and comorbid conditions, so there is no universal prognosis of tolerability. In case of any unusual symptoms not listed in the instructions, a medical specialist should be consulted to evaluate the benefit-risk ratio of continuing therapy. Unauthorized continuation of the drug in the presence of severe side effects is unacceptable.

Contraindications of VILAFINIL 200

Absolute contraindications to the use of VILAFINIL 200 are hypersensitivity to modafinil or any excipient of the drug, as well as a history of severe allergic reactions to other psychostimulants. The drug is strictly forbidden for patients diagnosed with hypertrophic cardiomyopathy, mitral valve prolapse with severe regurgitation, and other structural heart diseases accompanied by hemodynamic impairment. VILAFINIL 200 is not prescribed to persons with uncontrolled moderate to severe arterial hypertension, as the stimulating effect on the sympathetic nervous system can provoke a hypertensive crisis. The drug is also contraindicated in severe cardiac arrhythmias, particularly ventricular arrhythmias, and in cases of recent myocardial infarction or unstable angina.

Relative contraindications requiring special caution and careful weighing of risks are psychiatric disorders, including schizophrenia, bipolar disorder, and severe depression. In such patients, VILAFINIL 200 can provoke an exacerbation of psychotic symptoms or a manic episode, so prescribing is possible only under conditions of a stable mental state and parallel administration of adequate psychotropic therapy. The drug is not recommended for use during pregnancy, as animal studies have shown potential risk to the fetus, and controlled studies involving pregnant women have not been conducted. Women of childbearing potential should use reliable methods of contraception during therapy and for at least two months after its completion. During breastfeeding, the drug is also not used, as modafinil passes into breast milk.

Age under 18 years is a contraindication for the use of VILAFINIL 200 due to the lack of sufficient data on safety and efficacy in this population. For elderly patients over 65 years of age, the drug is prescribed with caution, in minimal effective doses, as the risk of side effects from the cardiovascular and nervous systems increases in this group. Patients with severe renal impairment should avoid using the drug or use it under strict monitoring of renal function. For persons with severe hepatic impairment, VILAFINIL 200 is contraindicated, as metabolic impairment can lead to the accumulation of the active substance in the body and increased toxic effects. Before starting therapy, it is mandatory to inform the doctor about all existing diseases and constantly taken medications.

Interaction of VILAFINIL 200 with other drugs and alcohol

VILAFINIL 200 is capable of entering into clinically significant interactions with a number of medicinal products, due to its effect on the cytochrome P450 enzyme system, in particular the CYP3A4 isoenzyme. The drug can reduce the effectiveness of hormonal contraceptives, so women taking oral contraceptives are recommended to use additional methods of protection during therapy and for two months after its completion. Concomitant use with anticoagulants, such as warfarin, requires regular monitoring of blood clotting parameters, as modafinil can alter their metabolism. Caution should also be exercised when combining VILAFINIL 200 with tricyclic antidepressants, selective serotonin reuptake inhibitors, and antiepileptic drugs, as mutual enhancement or weakening of therapeutic effects is possible.

Alcohol consumption during VILAFINIL 200 therapy is strictly not recommended, as ethanol can enhance the drug's central nervous system side effects, such as dizziness, impaired coordination, and decreased concentration. Furthermore, combining a stimulant with alcohol creates a false sense of sobriety, increasing the risk of dangerous behavior and accidents. Patients operating vehicles or machinery should exercise caution when starting the drug, as individual reactions may include drowsiness, dizziness, or visual disturbances. Until personal tolerability is established, it is recommended to refrain from driving a car and performing potentially hazardous activities. Any changes in the treatment regimen or the addition of new drugs must be agreed with a physician.

Where to buy VILAFINIL 200 in Ukraine

VILAFINIL 200 is available for purchase in Ukrainian pharmacy chains, as well as through specialized online platforms delivering medicinal products. The drug belongs to the category of prescription drugs, so its purchase may require an appropriate prescription from a doctor confirming the appropriateness of use. Capsules should be stored in a dry place, protected from light, at a temperature not exceeding 25 degrees Celsius, out of the reach of children. The shelf life of the drug is usually three years from the date of manufacture, after which the use of the product is strictly forbidden. Before purchasing, it is recommended to check the integrity of the packaging and the presence of protective holographic marking confirming the originality of the Fortune Healthcare product.

Patients should remember that VILAFINIL 200 is a serious pharmacological agent requiring a responsible attitude and mandatory consultation with a physician before starting intake. The individual response of the body to the drug can vary significantly, so self-medication or use of the product without medical supervision is unacceptable. Only a qualified specialist can assess the benefit-risk ratio, consider all contraindications, and select the optimal dosage regimen for a specific patient.